Affimed (AFMD) Stock Price, News & Analysis

Company Overview

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Key Stats

• Today's Range: $0.17 to $0.24
• 50-Day Range: $0.09 to $0.83
• 52-Week Range: $0.07 to $5.48
• Volume: 22.99 million shs
• Average Volume: 4.87 million shs
• Market Capitalization: $2.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.62
• Consensus Rating: Hold

Affimed Stock Analysis - MarketRank™

Affimed scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Affimed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Affimed has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Affimed are expected to grow in the coming year, from ($4.19) to ($2.05) per share.

Price to Book Value per Share Ratio

Affimed has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AFMD.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Affimed does not currently pay a dividend.

Dividend Growth

Affimed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.95

Short Interest

There is no current short interest data available for AFMD.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for AFMD on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Affimed to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Affimed insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.80% of the stock of Affimed is held by insiders.

Percentage Held by Institutions

Only 30.82% of the stock of Affimed is held by institutions.

AFMD Stock Analysis - Frequently Asked Questions

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) posted its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by $0.10. The biopharmaceutical company earned $10.21 million during the quarter, compared to the consensus estimate of $11.79 million. Affimed had a negative net margin of 7,836.26% and a negative trailing twelve-month return on equity of 193.84%.
Read the conference call transcript.

When did Affimed's stock split?

Affimed shares reverse split before market open on Monday, March 11th 2024.The 1-10 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Affimed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Affimed investors own include Meta Platforms (META), NVIDIA (NVDA), Novavax (NVAX), Tesla (TSLA), Advanced Micro Devices (AMD), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 7/26/2025
• Next Earnings (Estimated): 9/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AFMD
• CIK: 1608390
• Web: www.affimed.com
• Phone: 496221674360
• Fax: 49-6221-653-0777
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Affimed: $3.62
• High Price Target: $10.00
• Low Price Target: $0.10
• Potential Upside/Downside: +1,895.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$114.66 million
• Net Margins: -7,836.26%
• Pretax Margin: -7,837.50%
• Return on Equity: -193.84%
• Return on Assets: -107.24%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 1.93
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: $877 thousand
• Price / Sales: 3.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.19 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 16,100,000
• Free Float: 15,488,000
• Market Cap: $2.92 million
• Optionable: Optionable
• Beta: 2.07